Latest posts tagged with #MDSsm on Bluesky
At #SOHO2025, Asfand Yar Cheema of @clevelandclinic.bsky.social stopped by to share insights into the clinical outcomes of patients with #PolycythemiaVera or MDS treated with GLP-1 agonists.
Click here to watch the interview:
👉 buff.ly/KcqIbrj 👈
#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky
As today is World MDS Awareness Day, why not check out our MDS channel?🩸
You'll find the latest updates in MDS straight from leading experts in the form of video interviews, roundtable discussions, feature articles, podcasts, & more!🎥🎧
Click here to explore: 👉 buff.ly/aWAEu6k
#MDSWAD2025 #MDSsm
Today is MDS World Awareness Day!🩸🌎
In an interview from earlier this year, Valeria Santini discussed the use of immunosuppressive therapy in MDS, highlighting available agents & areas for further research:
👉 buff.ly/OsY3ebW 👈
#MDSWAD2025 #HemOnc #MDSsm #BloodSky #HemeSky #MedSky
At #SOHO2025, we caught up with Valeria Santini, who provided an overview of recent advances in the treatment of lower-risk MDS, with a focus on therapies for anemia.🩸
Click here to watch the interview:
👉 buff.ly/OBaMhs6 👈
#MDSsm #HemOnc #BloodSky #HemeSky #MedSky
🎥 Sanam Loghavi and Guillermo Montalban-Bravo of @mdanderson.bsky.social sat down at #iwAL25 to share insights into the diagnosis and classification of CMML, commenting on how the current approach to this could be refined:
👉 buff.ly/5ZwQxnP 👈
#Leusm #HemOnc #RareDisease #MDSsm #BloodSky #HemeSky
In an interview from #SOHO2025, Matteo Della Porta shares insights into the significance of anemia in MDS & MPNs, highlighting the need to develop effective therapies for this clinical feature.
Click to watch:
👉 buff.ly/rXyC3pf 👈
#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky
In an interesting interview from #SOHO2025, David Swoboda discusses the development of a novel AI-driven virtual tumor board designed to improve diagnosis, prognosis, and treatment recommendations in MDS.
Watch here:
🎥 buff.ly/wrh0OvA
#MDSsm #HemOnc #AI #BloodSky #HemeSky #MedSky
It was a pleasure to catch up with David Sallman of @moffittnews.bsky.social at #SOHO2025 to hear about promising novel concepts being explored for the treatment of TP53-mutated.🩸
Want to learn more?
Click here to watch:
👉 buff.ly/2rbgMwQ 👈
#MDSsm #HemOnc #BloodSky @societyofhemonc.bsky.social
Did you miss out on #SOHO2025?
Don’t worry! You can catch up with all the latest advancements from the meeting by checking out our exclusive interviews with leading #HemOnc experts below:
👉 buff.ly/tgyYWhf
#ImmunoOnc #LymSM #MPNsm #MDSsm #LeuSM #BloodSky #MedSky @societyofhemonc.bsky.social
In an insightful interview, Idoroenyi Amanam of @cityofhope.bsky.social discusses real-world data on the outcomes of US patients with lower-risk MDS treated with luspatercept in the first-line setting.
Click here to watch:
👉 buff.ly/EiFxYRa 👈
#MDSsm #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky
🎥 Shaun Fleming presents early safety and efficacy findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in patients with R/R AML or HR-MDS:
👉 buff.ly/GIoMPtN 👈
#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
How are clinical trials evolving in MDS?💭
At #iwMDS25, leading experts Maximilian Stahl, Rami Komrokji, & Coleman Lindsley discussed redefining response criteria & improving study design to advance care.🩸
Don’t miss this insightful session:
🎥 👉 buff.ly/cj2cXpS
#MDSsm #HemOnc #CTSM #BloodSky
At #iwMDS25, leading experts @abrunner.bsky.social, @mikkaelsekeres.bsky.social, & Lionel Ades shared insights into recent advances in the treatment & management of LR-MDS.🩸
Check out the roundtable discussion here:
👉 buff.ly/SkpE0p4 👈
#MDSsm #HemOnc #BloodSky #HemeSky #MedSky
Olutasidenib is Highly Effective in Certain Patients with Myelodysplastic Syndrome
#MDS #MDSSM #hematology
www.onclive.com/view/olutasi...
Want to hear about updates & advances in MDS classification & risk stratification?🩸
Watch our fantastic roundtable discussion from #iwMDS25 with experts Uma Borate, Luca Lanino, Robert Hasserjian, & @zoeyxie.bsky.social:
🎥 buff.ly/Yr2mKl8
#MDSsm #HemOnc #BloodSky #HemeSky #MedSky
Want to hear about updates & advances in MDS classification & risk stratification?🩸
Watch our fantastic roundtable discussion from #iwMDS25 with experts Uma Borate, Luca Lanino, Robert Hasserjian, & Zhuoer Xie:
🎥 buff.ly/UtUKM0w
#MDSsm #HemOnc #BloodSky #HemeSky #MedSky
Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification
@carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm
www.onclive.com/view/evoluti...
Oral Decitabine-Cedazuridine Is a Game Changer for MDS and CMML Treatment
#mdssm #leusm
www.onclive.com/view/oral-de...
Want a comprehensive overview of the current treatment options for patients with lower-risk MDS and anemia?🩸
Then don't forget to check out our fantastic interview with Valeria Santini from #EHA2025!😄
Watch here:
🎥 buff.ly/D4eOZ2R
#MDSsm #HemOnc #BloodSky #HemeSky #MedSky
The recent EHA 2025 Congress showcased novel combinations for MDS and AML as well as a novel formulation of a drug for B-ALL: an opinion piece by @ashkishtaagri.bsky.social of @vanderbilt.edu shorturl.at/RkY2M #EHA2025 #leusm #mdssm
Full text access to our review about iron chelation therapy in #MDSsm and allogeneic #HCT in Blood Reviews.
authors.elsevier.com/c/1lLPl,67Ou...
🚨 Hear results from the BEXMAB study investigating the efficacy of bexmarilimab plus azacitidine in MDS!
Watch our interview from #EHA2025 with Dr Mika Kontro here:
👉 buff.ly/HPeUP6m 👈
#MDSsm #CTSM #TrialUpdate #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
At #EHA2025 last week, Amer Zeidan gave an update on immune checkpoint inhibition in MDS & AML, highlighting the promise of novel agents sabatolimab and bexmarilimab.🩸
Watch the interview here:
👉 buff.ly/mVSYBHP
#AMLsm #MDSsm #Leusm #TrialUpdate #ImmunoOnc #BloodSky #HemeSky #CTSM
VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS
#MDS #mdssm
www.onclive.com/view/verona-...
news.abbvie.com/2025-06-16-A... Wow — top line VERONA results are negative — no advantage to AZA + VEN compared to AZA alone for higher-risk #MDSsm. AZA or DAC alone remain the standard for HR-MDS. So disappointing😢 🎗️🩸
Dr Amer Zeidan interviewing with VJHemOnc at EHA 2025
We've had a wonderful first day at #EHA2025! Thank you to Amer Zeidan of @yalecancer.bsky.social, who shared interesting insights into the use of immune checkpoint inhibition in MDS, the KOMET-017 trial, & more!
Stay tuned 👉VJHemOnc.com!
#MDSsm #HemOnc #LeuSM #AMLsm #BloodSky #CTSM #TrialUpdate
A real-world analysis found luspatercept more effective than ESAs for anemia treatment in patients with lower-risk MDS, according to research presented at #ASCO25. #MDSsm shorturl.at/IXHJo
#ASCO25 #mdssm Daver: Bexmarilimab in HR-MDS has excellent safety profile (13% dc for TEAE, IrAEs in 4%). ORR 72% in 1L, 63% in relapse. Encouraging responses in TP53m setting as well.
